Biomarkers used in determining the response to cytotoxic agents are not optimal for predicting benefit from anti-angiogenic drugs. Which anti-angiogenic biomarkers might prove useful for identifying initial drug choice, appropriate dosing, early clinical benefit, emerging resistance and second-line treatments?
- Adrian M. Jubb
- Adam J. Oates
- Hartmut Koeppen